Floatz logo

Imexon

Marginal Zone Lymphoma

University of RochesterSmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

106 Active assets in the Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Orelabrutinib
Henan Cancer Hospital
Phase 4BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
VINCRISTINE SULFATE
Mayo Clinic
Phase 2BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Imexon is also rated in:

pancreatic neoplasmDormant
B
Indicative ·
57 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
57 / 100
View asset →
lymphoplasmacytic lymphomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →